Premium
Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs
Author(s) -
Passmore C. A.,
Sherington J.,
Stegemann M. R.
Publication year - 2007
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/j.1748-5827.2006.00231.x
Subject(s) - medicine , urinary system , adverse effect , gastroenterology
O bjectives :To determine the efficacy and safety of cefovecin (Convenia TM ; Pfizer Animal Health) in the treatment of urinary tract infections in dogs.M ethods :A multi‐centre, blinded, randomised study was conducted in 129 dogs with urinary tract infections. Cephalexin (Rilexine TM ) administered twice daily at 15 mg/kg bodyweight orally for 14 days was compared with a single, subcutaneous injection of cefovecin (Convenia TM ) in dogs. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.R esults :One hundred and twenty‐nine dogs were included in efficacy assessments. Escherichia coli was eliminated in 90·5 per cent of cefovecin‐treated dogs compared with 52·9 per cent of cephalexin‐treated dogs (P=0·0004). Overall cure rates for dogs with Escherichia coli infections were 79·1 per cent for cefovecin and 36·4 per cent for cephalexin‐treated dogs (P=0·0003). There were no suspected adverse drug reactions attributed to treatment with cefovecin or cephalexin.C linical S ignificance :Cefovecin was shown to be an effective and safe treatment for urinary tract infections.